{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:27:47Z","timestamp":1793924867663,"version":"4.8.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.vaccine.2026.129171","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:08:21Z","timestamp":1792166901000},"page":"129171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cost-effectiveness of universal infant hepatitis B vaccination programme in Finland"],"prefix":"10.1016","volume":"94","author":[{"given":"Tanja","family":"Nieminen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markku","family":"Nurhonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuija","family":"Leino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heini","family":"Salo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129171_bb0005","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/lt.22388","article-title":"Cost of a quality-adjusted life year in liver transplantation: the influence of the indication and the model for end-stage liver disease score: cost per QALY in liver transplantation","volume":"17","author":"\u00c5berg","year":"2011","journal-title":"Liver Transpl"},{"key":"10.1016\/j.vaccine.2026.129171_bb0010","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/infdis\/151.4.604","article-title":"The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma","volume":"151","author":"Alward","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129171_bb0015","series-title":"Health and the use of health Services in Finland. Main findings of the Finnish health care survey 1995\/96 and changes from 1987 (no. 1998:5), Terveys","author":"Arinen","year":"1998"},{"key":"10.1016\/j.vaccine.2026.129171_bb0020","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.vaccine.2014.06.070","article-title":"Lasting immune memory against hepatitis B following challenge 10\u201311 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV\/Hib or monovalent hepatitis B vaccine at 3, 5 and 11\u201312 months of age","volume":"33","author":"Avdicova","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129171_bb0025","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/hec.625","article-title":"Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000)","volume":"10","author":"Beutels","year":"2001","journal-title":"Health Econ"},{"key":"10.1016\/j.vaccine.2026.129171_bb0030","doi-asserted-by":"crossref","unstructured":"Beutels, P., Edmunds, W.J., Antonanzas, F., Wit, G.A.D., Evans, D., Feilden, R., Fendrick, A.M., Ginsberg, G.M., Glick, H.A., Mast, E., Pechevis, M., Doorslaer, E.K.V., van Hout, B.A., Board, V.H.P., 2002. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 20, 1\u20137.","DOI":"10.2165\/00019053-200220010-00001"},{"key":"10.1016\/j.vaccine.2026.129171_bb0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/jinf.1998.0666","article-title":"The disease burden of hepatitis B in Uzbekistan","volume":"40","author":"Beutels","year":"2000","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2026.129171_bb0040","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1177\/0272989X02239651","article-title":"Economic evaluation of vaccination programs: the impact of herd-immunity","volume":"23","author":"Brisson","year":"2003","journal-title":"Med Decis Mak"},{"key":"10.1016\/j.vaccine.2026.129171_bb0045","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy353","article-title":"Cost-effectiveness of hepatitis B virus infection screening and treatment or vaccination in 6 high-risk populations in the United States","volume":"6","author":"Chahal","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129171_bb0050","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/eurpub\/cks067","article-title":"Changing epidemiology of hepatitis B and migration\u2013a comparison of six northern and North-Western European countries","volume":"23","author":"Chu","year":"2013","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.vaccine.2026.129171_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr7201a1","article-title":"Screening and testing for hepatitis B virus infection: CDC recommendations \u2014 United States, 2023","volume":"72","author":"Conners","year":"2023","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2026.129171_bb0060","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1111\/liv.14647","article-title":"Health related quality of life in chronic liver diseases","volume":"40","author":"Cortesi","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.vaccine.2026.129171_bb0065","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/14760584.2023.2161519","article-title":"A review of the DTaP-IPV-HB-PRP-T hexavalent vaccine in pediatric patients","volume":"22","author":"Dakin","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.129171_bb0070","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1002\/(SICI)1097-0258(19991215)18:23<3263::AID-SIM315>3.0.CO;2-3","article-title":"Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective","volume":"18","author":"Edmunds","year":"1999","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.129171_bb0075","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0035-9203(96)90539-8","article-title":"Vaccination against hepatitis B virus in highly endemic areas: waning vaccine-induced immunity and the need for booster doses","volume":"90","author":"Edmunds","year":"1996","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2026.129171_bb0080","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1098\/rspb.1993.0102","article-title":"The influence of age on the development of the hepatitis B carrier state","volume":"253","author":"Edmunds","year":"1993","journal-title":"Proc Biol Sci"},{"key":"10.1016\/j.vaccine.2026.129171_bb0085","series-title":"ECDC evidence brief: Prevention of hepatitis B and C in the EU\/EEA","author":"European Centre for Disease Prevention and Control (ECDC)","year":"2024"},{"key":"10.1016\/j.vaccine.2026.129171_bb0090","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.vaccine.2026.129171_bb0095","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/archpedi.153.2.126","article-title":"Clinical and economic impact of a combination Haemophilus influenzae and hepatitis B vaccine: estimating cost-effectiveness using decision analysis","volume":"153","author":"Fendrick","year":"1999","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.vaccine.2026.129171_bb0100","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0163-4453(96)80019-3","article-title":"An economic evaluation of universal vaccination against hepatitis B virus","volume":"32","author":"Fenn","year":"1996","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2026.129171_bb0105","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/ije\/dyi206","article-title":"A mathematical model to estimate global hepatitis B disease burden and vaccination impact","volume":"34","author":"Goldstein","year":"2005","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.129171_bb0110","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jcv.2003.09.016","article-title":"Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy","volume":"29","author":"Hahne","year":"2004","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2026.129171_bb0115","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1093\/infdis\/jiac088","article-title":"Assessing the cost-utility of universal hepatitis B vaccination among adults","volume":"226","author":"Hall","year":"2022","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129171_bb0120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1467-842X.2001.tb00566.x","article-title":"An economic evaluation of universal infant vaccination against hepatitis B virus using a combination vaccine (Hib-HepB): a decision analytic approach to cost effectiveness","volume":"25","author":"Harris","year":"2001","journal-title":"Aust N Z J Public Health"},{"key":"10.1016\/j.vaccine.2026.129171_bb0125","series-title":"General vaccination against hepatitis B revisited (no. 2008\/03E)","author":"Health Council of the Netherlands","year":"2009"},{"key":"10.1016\/j.vaccine.2026.129171_bb0130","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-2008-1040426","article-title":"Serologic diagnosis of acute and chronic viral hepatitis","volume":"11","author":"Hoofnagle","year":"1991","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.vaccine.2026.129171_bb0135","doi-asserted-by":"crossref","first-page":"8960","DOI":"10.1016\/j.vaccine.2011.09.042","article-title":"Preparing for the next public debate: universal vaccination against hepatitis B","volume":"29","author":"Houweling","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129171_bb0140","doi-asserted-by":"crossref","first-page":"7723","DOI":"10.1016\/j.vaccine.2010.09.068","article-title":"Public vaccination programmes against hepatitis B in the Netherlands: assessing whether a targeted or a universal approach is appropriate","volume":"28","author":"Houweling","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129171_bb0145","doi-asserted-by":"crossref","first-page":"460","DOI":"10.7326\/0003-4819-147-7-200710020-00004","article-title":"Cost-effectiveness of screening and vaccinating Asian and Pacific islander adults for hepatitis B","volume":"147","author":"Hutton","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2026.129171_bb0150","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1093\/clinids\/20.4.992","article-title":"Risks of chronicity following acute hepatitis B virus infection: a review","volume":"20","author":"Hyams","year":"1995","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.129171_bb0155","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/MEG.0b013e3282f340c8","article-title":"Estimating the future health burden of chronic hepatitis B and the impact of therapy in Spain","volume":"20","author":"Idris","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2026.129171_bb0160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00019053-199814030-00002","article-title":"Methodological quality of economic modelling studies: a case study with hepatitis B vaccines","volume":"14","author":"Jefferson","year":"1998","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.vaccine.2026.129171_bb0165","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1016\/j.vaccine.2015.06.084","article-title":"Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review","volume":"33","author":"Jit","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129171_bb0170","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v16.i18.2227","article-title":"Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure","volume":"16","author":"Kantola","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.vaccine.2026.129171_bb0175","doi-asserted-by":"crossref","first-page":"821","DOI":"10.7326\/0003-4819-142-10-200505170-00007","article-title":"Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis","volume":"142","author":"Kanwal","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2026.129171_bb0180","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.vaccine.2016.11.090","article-title":"Epidemiology of hepatitis B infection in Finland: implications for immunisation policy","volume":"35","author":"Karvonen","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129171_bb0185","series-title":"Health, functional capacity and welfare in Finland in 2011. (No. Report 68\/2012)","author":"Koskinen","year":"2012"},{"key":"10.1016\/j.vaccine.2026.129171_bb0190","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.2105\/AJPH.88.11.1638","article-title":"Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program","volume":"88","author":"Krahn","year":"1998","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2026.129171_bb0195","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/MEG.0b013e32830e289e","article-title":"High impact of migration on the prevalence of chronic hepatitis B in the Netherlands","volume":"20","author":"Marschall","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2026.129171_bb0200","series-title":"Guidelines for preparing a health economic evaluation Annex to decree 201\/2009","author":"Ministry of Social Affairs and Health","year":"2009"},{"key":"10.1016\/j.vaccine.2026.129171_bb0205","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/23744235.2022.2082519","article-title":"Health care costs related to hepatitis B in Finland are mostly due to chronic infections: a register-based study","volume":"54","author":"Nieminen","year":"2022","journal-title":"Infect Dis (Lond Engl)"},{"key":"10.1016\/j.vaccine.2026.129171_bb0210","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s12328-013-0447-1","article-title":"Management of hepatitis B virus-related acute liver failure","volume":"7","author":"Oketani","year":"2014","journal-title":"Clin J Gastroenterol"},{"key":"10.1016\/j.vaccine.2026.129171_bb0215","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.drugpo.2014.07.008","article-title":"Patterns and 14-year trends in mortality among illicit drug users in Finland: the HUUTI study","volume":"25","author":"Onyeka","year":"2014","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.vaccine.2026.129171_bb0220","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S0140-6736(81)90585-7","article-title":"Hepatocellular carcinoma and hepatitis B virus","volume":"318","author":"Palmer Beasley","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2026.129171_bb0225","author":"R Core Team"},{"key":"10.1016\/j.vaccine.2026.129171_bb0230","series-title":"Economic evaluations in adopting new vaccines in the Finnish national vaccination programme (doctoral dissertation)","author":"Salo","year":"2017"},{"key":"10.1016\/j.vaccine.2026.129171_bb0235","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.coph.2021.07.008","article-title":"Towards eradication of HBV: treatment approaches and status of clinical trials","volume":"60","author":"Sandmann","year":"2021","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.vaccine.2026.129171_bb0240","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/epirev\/mxj009","article-title":"Hepatitis B virus infection: epidemiology and vaccination","volume":"28","author":"Shepard","year":"2006","journal-title":"Epidemiol Rev"},{"key":"10.1016\/j.vaccine.2026.129171_bb0245","first-page":"432","article-title":"Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a north American urban population","volume":"22","author":"Sherman","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.vaccine.2026.129171_bb0250","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.vaccine.2010.10.075","article-title":"Economic evaluation of infant and adolescent hepatitis B vaccination in the UK","volume":"29","author":"Siddiqui","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129171_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15082388","article-title":"A historical overview on the role of hepatitis B and C viruses as aetiological factors for hepatocellular carcinoma","volume":"15","author":"Stroffolini","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.vaccine.2026.129171_bb0260","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107177","article-title":"Large variations in risk of hepatocellular carcinoma and mortality in treatment na\u00efve hepatitis B patients: systematic review with Meta-analyses","volume":"9","author":"Thiele","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2026.129171_bb0265","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/eurpub\/ckm123","article-title":"Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation","volume":"18","author":"Tilson","year":"2008","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.vaccine.2026.129171_bb0270","doi-asserted-by":"crossref","first-page":"f4057","DOI":"10.1136\/bmj.f4057","article-title":"Should Europe have a universal hepatitis B vaccination programme?","volume":"347","author":"Van Damme","year":"2013","journal-title":"BMJ"},{"issue":"Suppl. 4","key":"10.1016\/j.vaccine.2026.129171_bb0275","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-S4-05","article-title":"The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective","volume":"15","author":"Venook","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.vaccine.2026.129171_bb0280","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1016\/j.vaccine.2012.06.080","article-title":"Incidence of acute hepatitis B in different ethnic groups in a low-endemic country, 1992-2009: increased risk in second generation migrants","volume":"30","author":"Whelan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129171_bb0285","doi-asserted-by":"crossref","first-page":"664","DOI":"10.7326\/0003-4819-122-9-199505010-00004","article-title":"Cost-effectiveness of interferon-\u03b12b treatment for hepatitis B e antigen-positive chronic hepatitis B","volume":"122","author":"Wong","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2026.129171_bb0290","first-page":"369","article-title":"Hepatitis B vaccines: WHO position paper, July 2017","volume":"92","author":"World Health Organization","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.129171_bb0295","first-page":"405","article-title":"Hepatitis B vaccines: WHO position paper","volume":"84","author":"World Health Organization","year":"2009","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2026.129171_bb0300","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.vaccine.2026.129171_bb0305","author":"World Health Organization (WHO)"},{"key":"10.1016\/j.vaccine.2026.129171_bb0310","doi-asserted-by":"crossref","first-page":"11941","DOI":"10.3748\/wjg.v21.i42.11941","article-title":"Hepatitis B virus burden in developing countries","volume":"21","author":"Zampino","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"9203","key":"10.1016\/j.vaccine.2026.129171_b9000","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(99)07239-6","article-title":"Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity","volume":"355","year":"2000","journal-title":"Lancet"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009801?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009801?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:55:36Z","timestamp":1793922936000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":63,"alternative-id":["S0264410X26009801"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129171","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of universal infant hepatitis B vaccination programme in Finland","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129171","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129171"}}